Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2019-04-26 eCollection Date: 2019-06-01 DOI:10.2217/mmt-2018-0011

Evan S Weitman, Matthew C Perez, Daniel Lee, Youngchul Kim, William Fulp, Vernon K Sondak, Amod A Sarnaik, Ricardo J Gonzalez, Carl W Cruse, Jane L Messina, Jonathan S Zager

{"title":"Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins.","authors":"Evan S Weitman, Matthew C Perez, Daniel Lee, Youngchul Kim, William Fulp, Vernon K Sondak, Amod A Sarnaik, Ricardo J Gonzalez, Carl W Cruse, Jane L Messina, Jonathan S Zager","doi":"10.2217/mmt-2018-0011","DOIUrl":null,"url":null,"abstract":"Aim: To assess the impact of re-biopsy on partially sampled melanoma in situ (MIS), atypical melanocytic proliferation (AMP) and thin invasive melanoma.Materials & methods: We retrospectively identified cases of re-biopsied partially sampled neoplasms initially diagnosed as melanoma in situ, AMP or thin melanoma (Breslow depth ≤0.75 mm).Results & conclusion: Re-biopsy led to sentinel lymph node biopsy (SLNB) in 18.3% of cases. No patients upstaged from AMP or MIS had a positive SLNB. One out of nine (11.1%) initially diagnosed as a thin melanoma ≤0.75 mm, upstaged with a re-biopsy, had a positive SLNB. After re-biopsy 8.5% underwent an increased surgical margin. Selective re-biopsy of partially sampled melanoma with gross residual disease can increase the accuracy of microstaging and optimize treatment regarding surgical margins and SLNB.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2019-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2018-0011","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2018-0011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: To assess the impact of re-biopsy on partially sampled melanoma in situ (MIS), atypical melanocytic proliferation (AMP) and thin invasive melanoma.

Materials & methods: We retrospectively identified cases of re-biopsied partially sampled neoplasms initially diagnosed as melanoma in situ, AMP or thin melanoma (Breslow depth ≤0.75 mm).

Results & conclusion: Re-biopsy led to sentinel lymph node biopsy (SLNB) in 18.3% of cases. No patients upstaged from AMP or MIS had a positive SLNB. One out of nine (11.1%) initially diagnosed as a thin melanoma ≤0.75 mm, upstaged with a re-biopsy, had a positive SLNB. After re-biopsy 8.5% underwent an increased surgical margin. Selective re-biopsy of partially sampled melanoma with gross residual disease can increase the accuracy of microstaging and optimize treatment regarding surgical margins and SLNB.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

部分取样薄黑色素瘤的重新活检影响前哨淋巴结取样和手术边缘。

目的：评估重新活检对部分取样原位黑色素瘤（MIS）、非典型黑色素细胞增殖（AMP）和薄侵袭性黑色素瘤的影响。材料与方法：我们回顾性地确定了一些重新活检的部分取样肿瘤，最初诊断为原位黑色素瘤、AMP或薄黑色素瘤（Breslow深度≤0.75 mm）。结果与结论：18.3%的病例重新活检导致前哨淋巴结活组织检查（SLNB）。从AMP或MIS中抢出来的患者没有SLNB阳性。九分之一（11.1%）最初诊断为≤0.75 mm的薄黑色素瘤，经重新活检后，SLNB呈阳性。再次活检后，8.5%的患者手术切缘增加。对部分采样的伴有严重残留疾病的黑色素瘤进行选择性重新活检可以提高显微分期的准确性，并优化手术边缘和SLNB的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.